No•vill•a
noun
A biotechnology company working to develop groundbreaking therapeutics that bypass the most common route of administration- the bloodstream- so that effective therapeutics can be delivered to a site of action while avoiding exposure to the rest of the body. The result is fundamentally better therapeutics with full efficacy without side effects or addiction risks. And usher in the end of addicting painkillers.
Leadership Team
Dr. Shashi Kori
Dr. Shashi Kori is a Neurologist and Neuro-Oncologist with 22 years of research and teaching experience . He served as a founder and director at major universities such as USF and Duke University. With over 2 decades of experience in the drug development industry including GSK, Allergan, and MAP Pharmaceuticals, Dr. Kori brings a wealth of knowledge for medicine and the pharmaceutical industry.
Dr. Tracey Rapp
Dr. Rapp received her B.S in Chemistry from Purdue, M.S. in Analytical Chemistry from the University of Michigan, Ph.D. in Analytical Chemistry from the University of Michigan, and her M.S. in Quality Assurance and Regulatory Affairs from Temple University. With over 20 years of experience including 18 years at Pfizer and various small biotechs, Dr. Rapp brings an impressive knowledge of the pharmaceutical industry- from GxP work to in vivo, in vitro and clinicals.
Ajay Kori
Ajay is an entrepreneur with a history of solving big problems with novel solutions. Prior to founding Novilla, Ajay founded UrbanStems, Allay Lamp, Autodream and served as an Associate Director of Pet Meds heading the team launching Amazon’s first ever online pet pharmacy. He also worked at GlaxoSmithKline early in his career. Ajay obtained his BS in Chemistry from Duke University before attending Harvard Business School for his MBA.